Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

@article{Bellmunt2010ActivityOA,
  title={Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).},
  author={Joaquim Bellmunt and Jos{\'e} Manuel Trigo and Emiliano Calvo and Joan Carles and Jose Luis Perez-Gracia and Jordi Rubi{\'o} and J A Virizuela and Rafael Mart{\'i}n-Granizo L{\'o}pez and Mart{\'i}n L{\'a}zaro and J 1137 Albanell},
  journal={The Lancet. Oncology},
  year={2010},
  volume={11 4},
  pages={350-7}
}
BACKGROUND Maximum tolerated dose (MTD) chemotherapy followed by metronomic chemotherapy (low doses given on a frequent schedule) acts on tumour vascular endothelial cells by increasing the anti-tumour effect of anti-angiogenic agents. This multicentre, phase 2 study investigated the effectiveness of MTD gemcitabine combined with metronomic capecitabine plus the multikinase inhibitor sorafenib for the treatment of metastatic renal-cell carcinoma (RCC). METHODS Patients were enrolled at eight… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…